Eric Campeau

Eric Campeau

Company: Zenith Epigenetics

Job title: Senior Director, Translational Medicine


Eric has been involved in the preclinical and clinical development of the BET bromodomain inhibitor ZEN-3694 at Zenith Epigenetics Ltd.  With a background in epigenetics, chromatin biology, DNA repair, oncology, and metabolism, he contributed to the design of combination strategies and translational assays used in the Phases 1 and 2 of clinical trials of ZEN-3694 in breast and prostate cancer patients. His team identified potential mechanisms of action as well as biomarkers of response for ZEN-3694 in prostate cancer patients.


Panel: The Role of Epigenetics in an Oncology Portfolio 5:40 pm

Utilizing epigenetics in combination with immunotherapies to further bolster the immune response Building a differentiated oncology portfolio based on standalone epigenetic (mono)therapies Imagining the future of epigenetic therapies in oncology and beyondRead more

day: Virtual Conference Day

Design of combination strategies and identification of biomarkers associated with clinical response to the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients 5:00 pm

Optimal combination agents to use with BET bromodomain inhibitors in the clinic Patient populations that can benefit from combinatorial therapies with ZEN-3694 Biomarkers of response of ZEN-3694 + enzalutamide in mCRPC patientsRead more

day: Virtual Conference Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.